Sarepta Therapeutics (SRPT) EPS (Basic) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Sarepta Therapeutics (SRPT) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 86.03% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 37.21% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.73% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -38.31% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.51% |
| 10 | Sarepta Therapeutics | 2.36 Bn | 1.57 Bn | 251.87 Mn | 44.39% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.39% |
| Mar 31, 2026 | 36.40% |
| Dec 31, 2025 | -31.13% |
| Sep 30, 2025 | 15.17% |
| Jun 30, 2025 | 40.27% |
| Mar 31, 2025 | -56.30% |
| Dec 31, 2024 | 46.01% |
| Sep 30, 2024 | 37.23% |
| Jun 30, 2024 | 27.45% |
| Mar 31, 2024 | 29.76% |
| Dec 31, 2023 | 30.12% |
| Sep 30, 2023 | 43.11% |
| Jun 30, 2023 | 48.14% |
| Mar 31, 2023 | -194.74% |
| Dec 31, 2022 | 26.82% |
| Sep 30, 2022 | -19.98% |
| Jun 30, 2022 | 10.88% |
| Mar 31, 2022 | -4.05% |
| Dec 31, 2021 | 10.96% |
| Sep 30, 2021 | 19.46% |